A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19

Naeini, Mehri Bemani; Sahebi, Mahdieh; Nikbakht, Fateme; Jamshidi, Zahra; Ahmadimanesh, Mahnaz; Hashemi, Maryam; Ramezani, Javad; Miri, Hamid Heidarian; Yazdian‐Robati, Rezvan

doi:10.1016/j.obmed.2021.100323

Cited by 16 publications

(17 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding of a positive association of CKD and coronary atherosclerosis and other heart disease with severe COVID-19 illness has been well described at the epidemiologic level ( 22 ). We also found that people with neurocognitive disorders (including dementia and Alzheimer’s disease) were at a higher risk of severe COVID-19 illness, which could be associated with difficulties in access to care and difficulties in following safeguarding procedures ( 23 ).…”

Section: Discussionsupporting

confidence: 75%

“…The reasons for this finding are likely multifactorial and may include a reduced ability to prevent infection among patients with anxiety disorders, the immunomodulatory and/or cardiovascular effects of medications used to treat these disorders, or severe COVID-19 illness exacerbating anxiety disorders (19,20). In a subset of patients with pre-COVID encounters in our study, anxiety diagnosed before COVID-19 was not independently associated with death or IMV during COVID-19 hospitalization and, therefore, it is also plausible that anxiety was diagnosed during COVID-19 illness and may be a resulting sequela of COVID-19 (21). Future studies could explore the temporal and causal associations between anxiety disorders and severe COVID-19 illness.…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021

et al. 2021

View full text Add to dashboard Cite

In this cross-sectional study of 540,667 adult hospitalized patients with COVID-19, 94.9% had at least 1 underlying medical condition. Hypertension and disorders of lipid metabolism were the most frequent, whereas obesity, diabetes with complication, anxiety disorders, and the total number of conditions were the strongest risk factors for severe COVID-19 illness. What are the implications for public health practice?Preventing COVID-19 in populations with these underlying conditions and multiple conditions should remain a public health priority, with targeted mitigation efforts and ensuring high uptake of vaccine, when available, in these individuals and their close contacts.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 68%

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021

et al. 2021

View full text Add to dashboard Cite

show abstract

“…During 2020, many meta-analyses and meta-meta-analyses reported the positive association between underlying diseases, especially CVD, and the illness severity among COVID-19 patients [ 221 , 222 , 223 , 224 , 225 ]. Resveratrol can alleviate the numerous factors associated with CVD, so it has potential as a functional supplement to reduce COVID-19 illness severity in patients displaying poor prognosis.…”

Section: Resveratrol and Cvd Related To Covid-19mentioning

confidence: 99%

Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability

et al. 2021

View full text Add to dashboard Cite

Resveratrol is a phytoalexin produced by many plants as a defense mechanism against stress-inducing conditions. The richest dietary sources of resveratrol are berries and grapes, their juices and wines. Good bioavailability of resveratrol is not reflected in its high biological activity in vivo because of resveratrol isomerization and its poor solubility in aqueous solutions. Proteins, cyclodextrins and nanomaterials have been explored as innovative delivery vehicles for resveratrol to overcome this limitation. Numerous in vitro and in vivo studies demonstrated beneficial effects of resveratrol in cardiovascular diseases (CVD). Main beneficial effects of resveratrol intake are cardioprotective, anti-hypertensive, vasodilatory, anti-diabetic, and improvement of lipid status. As resveratrol can alleviate the numerous factors associated with CVD, it has potential as a functional supplement to reduce COVID-19 illness severity in patients displaying poor prognosis due to cardio-vascular complications. Resveratrol was shown to mitigate the major pathways involved in the pathogenesis of SARS-CoV-2 including regulation of the renin-angiotensin system and expression of angiotensin-converting enzyme 2, stimulation of immune system and downregulation of pro-inflammatory cytokine release. Therefore, several studies already have anticipated potential implementation of resveratrol in COVID-19 treatment. Regular intake of a resveratrol rich diet, or resveratrol-based complementary medicaments, may contribute to a healthier cardio-vascular system, prevention and control of CVD, including COVID-19 disease related complications of CVD.

show abstract

“…During 2020, many meta-analyses and meta-meta-analyses reported the positive association between underlying diseases, especially CVD, and the illness severity among COVID-19 patients [216][217][218][219][220]. Resveratrol can alleviate the numerous factors associated with CVD, so it has potential as a functional supplement to reduce COVID-19 illness severity in patients displaying poor prognosis.…”

Section: Resveratrol and Cvd Related To Covid-19mentioning

confidence: 99%

Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to Covid-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability

Gligorijević¹,

Stanić-Vučinić²,

Radomirović³

et al. 2021

Preprint

View full text Add to dashboard Cite

Resveratrol is a phytoalexin produced by many plants as a defense mechanism against stress-inducing conditions. The richest dietary sources of resveratrol are berries and grapes, their juices and wines. Good bioavailability of resveratrol is not reflected in its high biological activity in vivo because of resveratrol isomerization and its poor solubility in aqueous solutions. Proteins, cyclodextrins and nanomaterials have been explored as innovative delivery vehicles for resveratrol to overcome this limitation. Numerous in vitro and in vivo studies demonstrated beneficial effects of resveratrol in cardiovascular diseases (CVD). Main beneficial effects of resveratrol intake are cardioprotective, anti-hypertensive, vasodilatory, anti-diabetic, and improvement of lipid status. As resveratrol can alleviate the numerous factors associated with CVD, it has potential as a functional supplement to reduce COVID-19 illness severity in patients displaying poor prognosis due to cardio-vascular complications. Resveratrol was shown to mitigate the major pathways involved in the pathogenesis of SARS-CoV-2 including regulation of the renin-angiotensin system and expression of angiotensin-converting enzyme 2, stimulation of immune system and downregulation of pro-inflammatory cytokines release. Therefore, several studies already have anticipated potential implementation of resveratrol in COVID-19 treatment. Regular intake of resveratrol rich diet, or resveratrol-based complementary medicaments, may contribute to a healthier cardio-vascular system, prevention and control of CVD, including COVID-19 disease related complications of CVD.

show abstract

A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19

Cited by 16 publications

References 65 publications

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021

Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability

Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to Covid-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability

Contact Info

Product

Resources

About